17.30
-1.42%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vcanbio Cell & Gene Engineering Corp
Its shares trade on Shanghai under the ticker 600645.SS. It has been listed since 4 May 1993. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.45bn and net income of CN¥113.8m. At that date it held total assets of CN¥5.29bn and shareholders' equity of CN¥3.71bn.
Vcanbio Cell & Gene Engineering Corp., Ltd. engages in the development of life sciences technology. The company is headquartered in Tianjin, Tianjin. The firm is also engaged in cell culture and gene detection and storage, as well as the production and sale of cytokines culture solutions, cosmetics and detection reagents. The firm conducts its businesses mainly within domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 May 1993
- Employees
- 2,332
- Website
- vcanbio.com ↗
Leadership
Pay as last reported
- Mr. Hongjia GongChairman of the Board, since 2018
- Mr. Hongqi WangVice Chairman of the Board, General Manager, since 2023CN¥419,300
- Mr. Yong WangVice Chairman of the Board, since 2009CN¥1.9m
- Ms. Xiaoting WangFinance DirectorCN¥843,600
- Mr. Xinzhe YangDeputy General Manager, Secretary of the BoardCN¥1.0m
- Mr. Haibin LiDeputy General Manager, Director, since 2016CN¥1.1m
- Mr. Xu LiExecutive Deputy General Manager, Director, since 2015CN¥1.1m
- Mr. Hongxiang ShiDeputy General ManagerCN¥1.1m
- Mr. Yu ZhangDeputy General Manager, Chief R&D OfficerCN¥2.4m
- Ms. Jiali ZhouDeputy General ManagerCN¥977,300
- Ms. Shan WuDirector
- Mr. Xinyi HouIndependent DirectorCN¥100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 22
- Environment
- 18
- Social
- 14
- Governance
- 36
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vcanbio employs 2,332 full-time employees in Tianjin for biotechnology development.
- Vcanbio develops cell culture and gene detection solutions for domestic markets.
- Vcanbio produces cytokines culture solutions and detection reagents for health care.
Weaknesses
- Vcanbio's business is limited to domestic markets in China.
- Vcanbio's operations are based in Tianjin, China, restricting international reach.
- Vcanbio's product range includes cosmetics, which may not align with core biotechnology focus.
Opportunities
- Vcanbio can expand cell culture solutions into international health care markets.
- Vcanbio can leverage gene detection technology for global biotechnology applications.
- Vcanbio can grow cytokines culture solutions in the domestic health care sector.
Threats
- Vcanbio faces competition from domestic biotechnology firms in China.
- Vcanbio's reliance on domestic markets exposes it to local economic fluctuations.
- Vcanbio's cosmetics segment may face regulatory challenges in health care markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.